Renovaro enters definitive merger with AI-driven Biosymetrics for 15M shares

Lunai Bioworks Inc.

Renovaro issues 15M unregistered common shares to Biosymetrics stockholders for all outstanding shares; lock-up of CEO shares for 1 year.
3M of the issued shares held in escrow for 1 year to satisfy potential indemnification claims.
Merger expected to close by March 15, 2025, subject to Biosymetrics stockholder approval and Nasdaq listing.
Biosymetrics' Elion AI platform has partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.
Combined entity to focus on AI-driven biomarker discovery and precision medicine in cancer and other diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.